Medtronic Plc (MDT), a major player in the biotech sector, has been attracting a significant amount of investor attention and institutional shareholdings accounting for 85% of the company. Despite occasional underperformance in comparison to competitors, the stock is reported to have traded up consecutively over several sessions. There are mixed signals in the market as MDT has reported both gains and losses in various instances. However, important developments include FDA clearances of next-gen PillCam solution suite, an Inceptiv™ closed-loop spinal cord stimulator, and Evolut TAVR system. MDT has also reported favorable results for less-invasive HVAD pump and Sphere-360 PFA study, while its stock value has been suggested to be underestimated by some. The company has increased FY24 guidance following strong Q3 results and announced cash dividends for the financial year 2024. However, a series of potential issues, including weak financial prospects, downsizing reports, and legal tussles with rivals, have also been documented.
Medtronic Plc MDT News Analytics from Tue, 22 Aug 2023 07:00:00 GMT to Sun, 19 May 2024 10:56:49 GMT -
Innovation 5
- Information 7
- Rumor -2
